7 research outputs found
A Once-Weekly R207910-containing Regimen Exceeds Activity of the Standard Daily Regimen in Murine Tuberculosis
Rationale: R207910 (TMC207 or J) is a member of the diarylquinolines,
a new family of antituberculous drugs with high bactericidal
activity when given daily in the murine model of tuberculosis.
R207910 exhibits a long half-life and thus is a good candidate for
once-weekly therapy of tuberculosis.
Objectives: To study the activity of once-weekly R207910 monotherapy
and combinations of R207910 with other antituberculous agents
(isoniazid, rifapentine, moxifloxacin, and pyrazinamide).
Methods: The established infection model of murine tuberculosis was
used. Colony counts were determined in the lungs.
Measurements and Main Results: Eight weeksofmonotherapy reduced
the bacillary load by 3 to 4 log10 for rifapentine and by 5 to 6 log10 for
R207910 (P , 0.05). The addition of rifapentine and isoniazid or
moxifloxacin did not improve the bactericidal activity of R207910
monotherapy. In contrast, the triple combination of R207910 plus
rifapentine plus pyrazinamide given once weekly for 2 months (i.e.,
a total of only eight administrations), was significantly (P , 0.05)
more active than R207910 monotherapy or other R207910 combinations,
and led to lung culture negativity in 9 of 10 mice, whereas all
lungs were culture positive in the groups treated with other drug
combinations. Moreover, R207910 plus rifapentine plus pyrazinamide
given once weekly was more active than the current standard
regimen of rifampin plus isoniazid plus pyrazinamide given five
times per week.
Conclusions: The unprecedented activity of the triple combination of
R207910 plus rifapentine plus pyrazinamide suggests that it may be
feasible to develop a fully intermittent once-weekly regimen
Genetic Basis for Natural and Acquired Resistance to the Diarylquinoline R207910 in Mycobacteria
The atpE gene encoding the subunit c of the ATP synthase of Mycobacterium tuberculosis, the target of the new diarylquinoline drug R207910, has been sequenced from in vitro mutants resistant to the drug. The previously reported mutation A63P and a new mutation, I66M, were found. The genetic diversity of atpE in 13 mycobacterial species was also investigated, revealing that the region involved in resistance to R207910 is conserved, except in Mycobacterium xenopi in which the highly conserved residue Ala63 is replaced by Met, a modification that may be associated with the natural resistance of M. xenopi to R207910
A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis
Rationale: R207910 (TMC207 or J) is a member of the diarylquinolines,
a new family of antituberculous drugs with high bactericidal
activity when given daily in the murine model of tuberculosis.
R207910 exhibits a long half-life and thus is a good candidate for
once-weekly therapy of tuberculosis.
Objectives: To study the activity of once-weekly R207910 monotherapy
and combinations of R207910 with other antituberculous agents
(isoniazid, rifapentine, moxifloxacin, and pyrazinamide).
Methods: The established infection model of murine tuberculosis was
used. Colony counts were determined in the lungs.
Measurements and Main Results: Eight weeksofmonotherapy reduced
the bacillary load by 3 to 4 log10 for rifapentine and by 5 to 6 log10 for
R207910 (P , 0.05). The addition of rifapentine and isoniazid or
moxifloxacin did not improve the bactericidal activity of R207910
monotherapy. In contrast, the triple combination of R207910 plus
rifapentine plus pyrazinamide given once weekly for 2 months (i.e.,
a total of only eight administrations), was significantly (P , 0.05)
more active than R207910 monotherapy or other R207910 combinations,
and led to lung culture negativity in 9 of 10 mice, whereas all
lungs were culture positive in the groups treated with other drug
combinations. Moreover, R207910 plus rifapentine plus pyrazinamide
given once weekly was more active than the current standard
regimen of rifampin plus isoniazid plus pyrazinamide given five
times per week.
Conclusions: The unprecedented activity of the triple combination of
R207910 plus rifapentine plus pyrazinamide suggests that it may be
feasible to develop a fully intermittent once-weekly regimen
Should Moxifloxacin Be Used for the Treatment of Extensively Drug-Resistant Tuberculosis? An Answer from a Murine Modelâ–¿
The prevalence of extensively drug-resistant tuberculosis (XDR-TB), defined as TB that is resistant to isoniazid, rifampin, fluoroquinolones, and aminoglycosides, is rising worldwide. The extent of Mycobacterium tuberculosis resistance to fluoroquinolones depends on the mutation in the DNA gyrase, the only target of fluoroquinolones. The MIC of moxifloxacin, the most active fluoroquinolone against M. tuberculosis, may be lower than its peak serum level for some ofloxacin-resistant strains of Mycobacterium tuberculosis. Therefore, if the MIC of moxifloxacin is lower than its peak serum level, it may be effective against XDR-TB. Our objective was to determine the efficacy of moxifloxacin in treating ofloxacin-resistant TB. We selected isogenic fluoroquinolone-resistant mutants of M. tuberculosis H37Rv in vivo. We infected Swiss mice with either wild-type H37Rv or one of three mutant strains with different MICs that are commonly seen in clinical practice. The MICs of the mutant strains ranged from below to above the peak moxifloxacin level seen in humans (3 μg/ml). Each mouse was treated with one of four moxifloxacin doses for 1 month. Moxifloxacin was effective against mutant strain GyrB D500N, with the lowest MIC (0.5 μg/ml), when the standard dose was doubled. Moxifloxacin reduced mortality in mice infected with mutant strain GyrA A90V with an intermediate MIC (2 μg/ml). However, it had no impact on the mutant strain GyrA D94G with the highest MIC (4 μg/ml). Our study underscores current WHO recommendations to use moxifloxacin when there is resistance to early-generation fluoroquinolones such as ofloxacin, restricting this recommendation to strains with moxifloxacin MICs of less than or equal to 2 μg/ml
Population Genomics of Mycobacterium leprae Reveals a New Genotype in Madagascar and the Comoros
Human settlement of Madagascar traces back to the beginning of the first millennium with the arrival of Austronesians from Southeast Asia, followed by migrations from Africa and the Middle East. Remains of these different cultural, genetic, and linguistic legacies are still present in Madagascar and other islands of the Indian Ocean. The close relationship between human migration and the introduction and spread of infectious diseases, a well-documented phenomenon, is particularly evident for the causative agent of leprosy, Mycobacterium leprae. In this study, we used whole-genome sequencing (WGS) and molecular dating to characterize the genetic background and retrace the origin of the M. leprae strains circulating in Madagascar (n = 30) and the Comoros (n = 3), two islands where leprosy is still considered a public health problem and monitored as part of a drug resistance surveillance program. Most M. leprae strains (97%) from Madagascar and Comoros belonged to a new genotype as part of branch 1, closely related to single nucleotide polymorphism (SNP) type 1D, named 1D-Malagasy. Other strains belonged to the genotype 1A (3%). We sequenced 39 strains from nine other countries, which, together with previously published genomes, amounted to 242 genomes that were used for molecular dating. Specific SNP markers for the new 1D-Malagasy genotype were used to screen samples from 11 countries and revealed this genotype to be restricted to Madagascar, with the sole exception being a strain from Malawi. The overall analysis thus ruled out a possible introduction of leprosy by the Austronesian settlers and suggests a later origin from East Africa, the Middle East, or South Asia